Efficacy of Intravitreal Aflibercept Injection (IAI) Administered in a Treat and Extend Fashion in Patients With Center Involved Diabetic Macular Edema (DME) Previously Managed With 0.3 mg Intravitreal Ranibizumab
Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 20 Jun 2018
Price : $35 *
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- 12 Jun 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 18 Apr 2018 Planned End Date changed from 30 Mar 2019 to 30 Sep 2020.
- 18 Apr 2018 Planned primary completion date changed from 30 Dec 2018 to 30 Jun 2020.